Sunitinib is the first-line treatment for advanced RCC, although 77–92% of patients receiving vascular endothelial growth factor pathway inhibitors experience adverse cardiovascular events of any grade or proteinuria during the treatment period [35]. Here, VEGFA is linked to renal cell carcinoma.